PNEUMOSTEM®: PNEUMOSTEM® will be administered intratracheally as a single dose of 2.0x10000000 cells/kg on Day 1.
Study summary
The goal of this clinical trial is to evaluate the safety and potential efficacy of PNEUMOSTEM® for improving respiratory outcomes in very premature infants diagnosed with Early Pulmonary Arterial Hypertension. The main questions it aims to answer are:
* In very premature infants diagnosed with early pulmonary arterial hypertension, will a single intratracheal administration of PNEUMOSTEM®(Allogeneic umbilical cord blood-derived mesenchymal stem cells) result in improvement of pulmonary arterial hypertension based on echocardiographic assessment?
* In very premature infants diagnosed with early pulmonary arterial hypertension who show improvement of pulmonary arterial hypertension based on echocardiographic assessment following a single intratracheal administration of PNEUMOSTEM®(Allogeneic umbilical cord blood-derived mesenchymal stem cells), at what time point does this improvement occur?
Participants will:
* Single intratracheal dose of PNEUMOSTEM® at 2.0 x 10,000,000 cells/kg
* Acute adverse event monitoring: 24 hours post-administration for safety assessment
* Follow- up time points: Day 1(Baseline, PNEUMOSTEM® administration), Day 2, Week 1, Week 2, Postnatal Day 28, PMA 36\~40 weeks
Eligibility
Sex
ALL
Min age
1 Day
Max age
14 Days
Healthy volunteers
No
Inclusion Criteria:
1. Premature infants within 2 weeks of birth with a gestational age of 28 weeks or less or birth weight of less than 1,250g who require continuous invasive mechanical ventilation
2. When diagnosed with early pulmonary arterial hypertension satisfying condition ① or ② up to 14 days after birth:
* When on or more of the following abnormal findings are present on echocardiography performed between 4 and 14 days after birth (findings at 1-3 days after birth correspond to early neonatal transition):
1. Sytemic or suprasystemic pulmonary artery pressure \>40mmHg(based on peak Doppler velocity of tricuspid regurgitation)
2. Right-to-left or bidirectional shunt through patent ductus arteriosus, foramen ovale, or atrial septal defect
3. Flattened interventricular septum or D-shaped left ventricle at end systole ② When receiving nitric oxide(NO) inhalation therapy for persistent pulmonary hypertension of the newborn(PPHN) within 3 days after birth
Exclusion Criteria:
1. Those witth cyanotic congenital heart defects or acyanotic congenital heart defects causing heart failure, excluding patent ductus arteriosus in premature infatns
2. Those with severe pulmonary malformations such as congenital diaphragmatic hernia or congenital cystic lung disease
3. Those who underwent surgery within 72 hours before or after administration of the investigational cell product, or those for whom surgery is anticipated
4. Those who received surfactant within 24 hours prior to administration of the investigattional cell product
5. Those with chromosomal abnormalities accompanied by severe malformations(such as Edwards syndrome, Patau syndrome, Down syndrome, etc.) and severe congenital malformations(such as hydrocephalus, encephalocele, etc.)
6. Those with severe congenital infectious diseases(such as herpes, toxoplasmosis, rubella, syphilis, AIDS, etc.)
7. Those with severe sepsis or shock due to active infection not adequately treated with antibiotics
8. Those who have a history of participation in other advanced regenerative medicine clinical studies or clinical trials
9. Others deemed inappropriate by tthe investigator to participate in this advanced regenerative medicine clinical study
Primary outcome measure(s)
Time point(week) of complete reversal of cardiac shunt direction — Biweekly from day after PNEUMOSTEM administration until postnatal day 28 Time from PNEUMOSTEM administration to complete reversal of intracardiac shunt from right-to-left to complete left-to-right direction, as assessed by echocardiography.
Time to normalization of ventricular septal configuration — Once between postnatal day 28 and PMA 36~40 weeks Time from PNEUMOSTEM administration to resolution of flattened interventricular septum or disappearance of D-shaped left ventricle at end-systole, as assessed by echocardiography.
Change in duration of pulmonary hypertension medication use — Daily on PNEUMOSTEM administration day and the next day Change in duration of pulmonary hypertension medication use by medication type following PNEUMOSTEM administration compared to standard care. Duration will be measured in days for each medication type used to treat pulmonary hypertension.
Change in duration of mechanical ventilation — Weekly at week 1 and week 2 after PNEUMOSTEM administration Change in total duration of mechalical ventilator use following PNEUMOSTEM andministration compared to standard care. Duration will be measured in days from initiation to discontinuation of mechanical ventilation.
Change in duration of supplemental oxygen therapy. — Weekly at week 1 and week 2 after PNEUMOSTEM administration Change in total duration of supplemental oxygen use following PNEUMOSTEM administration compared to standard care. Duration will be measured in days from initiation to discontinuation of oxygen therapy.
Incidence of Bronchopulmonary Dysplasia(BPD) — At postnatal day 28 and at between PMA 36~40 weeks Inicidence of bronchopulmonary dysplasia assessed according to standard diagnostic criteria(requirement for supplemental oxygen at 28 days of postnatal age and/or at 36 weeks postmenstrual age).
Severity of Bronchopulmonary Dysplasia(BPD) — At postnatal day 28 and at between PMA 36~40 weeks Severity assessment of bronchopulmonary dysplasia categorized according to the definition of NIHCD 2001, NICHD 2018 and JENSEN 2019.
Incidence of Retinopathy of Prematurity(ROP) — Once at between PMA 36~40 weeks Incidence of retinopathy of prematurity assessed by ophthalmologic examination according to the International Classification of Retinopathy of Prematurity.
Severity of Retinopathy of Prematurity(ROP) — Once at between PMA 36~40 weeks Severity assessment of retinopathy of prematurity including staging(Stage 1\~5), zone(Zone I, II, or III), and presence of pulse disease. Assessment of treatment requirements including lase photocoagulation, anti-VEGF injection, or surgical intervention.
Time point of brain injury ditection on Brain MRI — Once at between PMA 36~40 weeks Time point of early detection of brain injury or neurodevelopmental abnormalities on brain MRI performed at postmenstrual age 36\~40 weeks. Brain injuries assessed include intraventricular hemorrhage, periventricular leukomalacia, and other structural abnormalities.
Incidence of Respiratory-related mortality — From PNEUMOSTEM administration to PMA 36~40 weeks Incidence of respiratory-related moratlity confirmed by medical records and information survey. Respiratory-related mortality is defined as death primarily attributed to respiratory failure, pulmonary hypertension, or complications of bronchopulmonary dysplasia.
Tiem point of respiratory-related mortality — From PNEUMOSTEM administration to PMA 36~40 weeks Postnatal age(in days) at which respiratory-related death occurs in participants who experience this outcome. Time will be measured from PNEUMOSTEM administration to the date of death.
Trial sites (1)
Facility
City
Region
Status
Samsung Medical Center, 81, Irwon-ro, Gangnam-gu, Seoul, Republic of Korea
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
